reports
- ABGSC Capital Goods Research
- Anders Idborg
- Karl Bokvist
- Olof Cederholm
VOLV B VOLVO AB CLASS B
WRT1V WARTSILA OYJ ABP
ABB ABB LTD.
SAND SANDVIK AB
TREL B TRELLEBORG AB CLASS B
MOCORP METSO OUTOTEC OYJ
ASSA B ASSA ABLOY AB CLASS B
SKF B SKF AB CLASS B
HPOL B HEXPOL AB CLASS B
ALFA ALFA LAVAL AB
MTRS B MUNTERS GROUP
HEXA B HEXAGON AB
EPI A EPIROC AB
NIBE B NIBE INDUSTRIER AB
ATCO A ATLAS COPCO AB
ALIV SDB AUTOLIV INC.
Trading by management and close relations of management
Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of Novonesis Group reports the transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B in the attached file. Investor Relations Tobias Bjorklund Anders Enevoldsen Disa Tuominen Attachment
- Alexander Aukner
LSG LEROY SEAFOOD GROUP ASA
AUSS AUSTEVOLL SEAFOOD ASA
AKVA AKVA GROUP ASA
SALM SALMAR ASA
GSF GRIEG SEAFOOD ASA
MOWI MOWI ASA
BAKKA BAKKAFROST P/F
SALMOCAM SALMONES CAMANCHACA SA
IFISH ICE FISH FARM AS
ASA ATLANTIC SAPPHIRE
SALME SALMON EVOLUTION HOLDING
KING THE KINGFISH COMPANY NV
AKBM AKER BIOMARINE
ISLAX ARNARLAX AS
AFISH ARCTIC FISH HOLDING AS
MAS MÅSØVAL
Borregaard ASA: Reporting of transactions in Borregaard ASA's shares m...
Borregaard ASA: Reporting of transactions in Borregaard ASA's shares made by person discharging managerial responsibilities Today, primary insider Liv Longva, Senior Vice President (SVP), exercised 15,000 stock options at a strike price of NOK 87.60 per share and in separate transactions, purchased and sold the same number of shares. The shares are drawn from Borregaard’s holdings of treasury shares. Please, see attached notifications for persons discharging managerial responsibilities in Borregaard in accordance with Regulation EU 596/2014 (MAR) article 19. After the transactions, Liv L...
- Alexander Aukner
Lerøy Seafood (Hold, TP: NOK55.00) - Progress with new technology
Q1 operating EBIT of NOK842m was c4% below our estimate, but 3% above consensus. New shielding and submersible technologies are reported to work well, with strong biological performance in Q1. The company guides for costs in line to slightly higher than in 2023, and while the 2024 harvest guidance was maintained, 2025 was cut 5kt from Sjøtroll. We have reduced our 2024e EPS by 6.0%, but increased 2025–2026e by 0.5–3.6%. We have downgraded to HOLD (BUY), with a raised target price of NOK55 (52).
- ABGSC Seafood Research
- Martin Kaland
- Simon Brun
- ABGSC Pulp & Paper Research
- Ali Shemmari
- Martin Melbye
- Alexander Aukner
Lerøy Seafood (Buy, TP: NOK52.00) - Q1 in line and operational progres...
Q1 operating EBIT was NOK842m, 4% below our estimate, but 3% above consensus. Farming EBIT fell shy of expectations, while wildcatch and VAP were above. Operational performance in farming stated to go well, with good growth and biology in all regions, helped by shielding technologies. The 2024 harvest guidance was unchanged at 175kt (consensus: 161–167kt). We expect consensus 2024e EPS to come up 0–2% and the stock 2–5% on improved sentiment regarding an operational turnaround.
- ABGSC Seafood Research
- Martin Kaland
- Simon Brun
Lerøy Seafood Group ASA: Progress in biological performance. Promising...
Lerøy Seafood Group ASA: Progress in biological performance. Promising shielding technology enhances fish welfare. GOOD BIOLOGICAL DEVELOPMENT IN THE FIRST QUARTER OF 2024. PROGRESS IN VAP S&D CONTINUES. Today, Lerøy Seafood Group ASA reports a consolidated operational EBIT of MNOK 842 for the first quarter of 2024. Of this, Farming accounts for MNOK 576, with seasonally low harvest volumes. CEO Henning Beltestad says; We have had a good quarter in Farming with strong biological development. Considering the very cold sea temperatures, our fish are growing well. It is also very pleasing...
Lerøy Seafood Group ASA: Fremgang i biologisk prestasjon. Lovende skje...
Lerøy Seafood Group ASA: Fremgang i biologisk prestasjon. Lovende skjermingsteknologi løfter fiskevelferd. GOD BIOLOGISK UTVIKLING I FØRSTE KVARTAL 2024. FREMGANGEN I VAP S&D FORTSETTER. Lerøy Seafood Group ASA rapporterer i dag et konsolidert operasjonelt driftsresultat på MNOK 842 for første kvartal 2024. Av dette utgjør havbruk MNOK 576, på sesongmessig lave slaktevolumer. Konsernleder Henning Beltestad sier; Vi har hatt et godt kvartal i Havbruk med en sterk biologisk utvikling. I lys av svært kalde sjøtemperaturer vokser fisken vår godt. Det er også veldig gledelig å konstatere be...
Borregaard ASA: Reporting of transactions in Borregaard ASA's shares m...
Borregaard ASA: Reporting of transactions in Borregaard ASA's shares made by person discharging managerial responsibilities Today, primary insider Kristin Misund, Senior Vice President, exercised 15,000 stock options at a strike price of NOK 87.60 per share, and in separate transactions, purchased and sold the same number of shares. The shares are drawn from Borregaard’s holdings of treasury shares. Please, see attached notifications for persons discharging managerial responsibilities in Borregaard in accordance with Regulation EU 596/2014 (MAR) article 19. After the transactions, Kristi...
- Geir Hiller Holom
Nykode Therapeutics (Buy, TP: NOK31.00) - Q1 report and Merck collabor...
While the Q1 report contained no large surprises (the expected upcoming events near-term seem on track), the company also announced a collaboration with MSD (Merck) to evaluate VB10.16 in combination with KEYTRUDA (pembrolizumab) in patients with HPV16-associated high-risk locally advanced cervical cancer. Management is due to present the results at a live-streamed webcast at 16:00 CET today.
- ABGSC Healthcare Research
- Alexander Krämer
- ABGSC IT Research
- Daniel Thorsson
- Simon Granath
Nykode Therapeutics Announces Clinical Collaboration with MSD to Evalu...
Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer OSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that it has expanded its collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA) to include a clinical trial collaboration and supply agreement for a phase 2 trial evaluating N...
Nykode Therapeutics - Quarterly report Q1 2024
Nykode Therapeutics - Quarterly report Q1 2024 OSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced its unaudited financial results for the first quarter of 2024. The financial report can be accessed in the Investors section of the Company’s website: . The Company will host a webcast presentation at 4 p.m. CET / 10 a.m. ET. A live and archived webcast of the presentation can be accessed in the Investors section of the ...
- ABGSC Chemicals Research
- Bengt Jonassen
- Martin Melbye
- Alexander Aukner
LSG LEROY SEAFOOD GROUP ASA
AUSS AUSTEVOLL SEAFOOD ASA
AKVA AKVA GROUP ASA
SALM SALMAR ASA
GSF GRIEG SEAFOOD ASA
MOWI MOWI ASA
BAKKA BAKKAFROST P/F
SALMOCAM SALMONES CAMANCHACA SA
IFISH ICE FISH FARM AS
ASA ATLANTIC SAPPHIRE
SALME SALMON EVOLUTION HOLDING
KING THE KINGFISH COMPANY NV
AKBM AKER BIOMARINE
ISLAX ARNARLAX AS
AFISH ARCTIC FISH HOLDING AS
MAS MÅSØVAL
Trelleborg AB: 1 director
A director at Trelleborg AB bought 1,600 shares at 36.084USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.